Analysts Set Expectations for ENVB Q4 Earnings

Enveric Biosciences, Inc. (NASDAQ:ENVB) – Investment analysts at HC Wainwright issued their Q4 2024 EPS estimates for shares of Enveric Biosciences in a research note issued on Thursday, March 6th. HC Wainwright analyst V. Bernardino forecasts that the company will earn ($0.23) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Enveric Biosciences’ current full-year earnings is ($31.18) per share. HC Wainwright also issued estimates for Enveric Biosciences’ FY2025 earnings at ($0.86) EPS.

Enveric Biosciences Price Performance

Shares of Enveric Biosciences stock opened at $1.70 on Monday. Enveric Biosciences has a fifty-two week low of $1.13 and a fifty-two week high of $28.05. The firm has a fifty day moving average price of $3.37 and a two-hundred day moving average price of $5.36. The company has a market cap of $1.15 million, a PE ratio of -0.04 and a beta of 0.47.

Institutional Trading of Enveric Biosciences

An institutional investor recently raised its position in Enveric Biosciences stock. AdvisorShares Investments LLC raised its stake in Enveric Biosciences, Inc. (NASDAQ:ENVB) by 63.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 599,854 shares of the company’s stock after purchasing an additional 232,807 shares during the period. AdvisorShares Investments LLC owned approximately 88.21% of Enveric Biosciences worth $215,000 as of its most recent SEC filing. 13.82% of the stock is owned by institutional investors and hedge funds.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.